...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Oncology letters >Impact of metastatic status on the prognosis of EGFR mutation-positive non-small cell lung cancer patients treated with first-generation EGFR-tyrosine kinase inhibitors
【24h】

Impact of metastatic status on the prognosis of EGFR mutation-positive non-small cell lung cancer patients treated with first-generation EGFR-tyrosine kinase inhibitors

机译：转移地位对先代EGFR-酪氨酸激酶抑制剂治疗EGFR突变阳性非小细胞肺癌患者预后的影响

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The aim of the present study was to analyze the impact of metastatic status on the prognosis of epithelial growth factor receptor (EGFR) mutation-positive patients with non-small cell lung cancer (NSCLC) treated with first-generation EGFR-tyrosine kinase inhibitors (TKIs). A total of 178 EGFR mutation-positive patients with stage IIIB-IV and relapsed NSCLC who were treated with gefitinib or erlotinib as the first-line treatment were enrolled in the present study. Metastatic status, progression-free survival (PFS), overall survival (OS) and treatment-response rates were investigated. The association between the number of metastatic organ sites and patient prognosis was also investigated. The median age at the time of treatment was 72 (range, 39-91) years. A total of 168 patients had adenocarcinoma; 156 were treated with gefitinib. Patients with brain metastases, bone metastases, liver metastases and pleural effusion exhibited a significantly reduced PFS and OS time in the univariate analysis, compared with patients without each of these symptoms. In the multivariate analysis, bone metastasis was associated with a poorer PFS (hazard ratio, 2.11; 95% confidence interval, 1.44-3.09; P<0.001) and brain metastasis was associated with a poorer OS (hazard ratio, 2.41; 95% confidence interval, 1.46-3.95; P<0.001). No association was observed between metastatic status and treatment response rates. Higher numbers of different sites of organ metastases were associated with significantly poorer PFS and OS. Bone, brain metastasis and higher numbers of metastatic organ sites are negative prognostic factors for EGFR mutation-positive NSCLC patients treated with first-generation EGFR-TKIs.
机译：本研究的目的是分析转移状态对上皮生长因子受体（EGFR）突变阳性患者的非小细胞肺癌（NSCLC）的预后的影响（ TKIS）。在本研究中，共有178例患有吉维替尼或奥尔洛替尼治疗的IIIB-IV阶段和复发的NSCLC的EGFR突变患者。研究了转移状态，无进展生存（PFS），总体存活（OS）和治疗 - 反应率进行了研究。还研究了转移器官网站和患者预后之间的关联。治疗时的中位年龄为72（范围，39-91）岁。共有168名患者腺癌;用吉替尼治疗156。患有脑转移，骨转移，肝转移和胸腔积液的患者在单变量分析中表现出显着降低的PFS和OS时间，与没有每种症状的患者相比。在多变量分析中，骨转移与较差的PFS（危险比，2.11; 95％置信区间，1.44-3.09; p <0.001）和脑转移与较差的OS（危险比，2.41; 95％信心有关间隔，1.46-3.95; p <0.001）。转移状态和治疗响应率之间没有观察到关联。更高数量的器官转移位点与显着较差的PFS和OS相关。骨骼，脑转移和较高数量的转移器官位点是用第一代EGFR-TKI治疗的EGFR突变阳性NSCLC患者的负预后因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号